Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial)
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Dexmedetomidine, an alpha 2-adrenoreceptor agonist, has been found to exerts an excellent
influences on the filed of perineural block. It could shorten the onset time and prolong the
duration of the nerve block and improved postoperative pain. However, Dexmedetomidine-induced
bradycardia or hypotension has recently attracted considerable attention because of
potentially grave consequences, including sinus arrest and refractory cardiogenic shock. A
low dose may help minimize cardiovascular risks associated with dexmedetomidine. However, few
studies have addressed the clinical effects of low-dose dexmedetomidine as an perineural
adjuvant. The present study was designed to test the hypothesis that low-dose dexmedetomidine
added to ropivacaine would safely enhance the duration of analgesia without adverse effects
when compared with ropivacaine alone. Investigators will conduct a single-center,
prospective, randomized, triple-blind, controlled trial in patients undergoing elective
forearm and hand surgery under ultrasound-guided supraclavicular brachial plexus block using
either ropivacaine or ropivacaine plus low-dose dexmedetomidine. The primary outcome is
self-reported duration of analgesia . Secondary outcomes include onset time and duration of
motor and sensory block, total postoperative analgesics, and safety assessment (adverse
effects and postoperative abnormal sensation).
Phase:
Phase 4
Details
Lead Sponsor:
Guangzhou First Municipal People’s Hospital Guangzhou First People's Hospital